Results 101 to 110 of about 6,160,075 (249)
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
ÐÑоÑеÑÑионалÑÐ½Ð°Ñ Ð¸ ÑизиÑеÑÐºÐ°Ñ Ð¿Ð¾Ð´Ð³Ð¾Ñовка военноÑлÑжаÑÐ¸Ñ Ð¡Ð¨Ð
Валерий Александрович Щеголев +1 more
openalex +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
D. Seifried, N. Stark: Energiedienstleistungen
TATuP editorial office
doaj +1 more source
Gauge covariant link formulation of twisted N = D = 4 and N = 4 D = 5 super Yang-Mills on a lattice
We propose a lattice formulation of four dimensional super Yang-Mills model with a twisted N = 4 supersymmetry in a manifestly gauge covariant manner. The formulation we employ here is a four dimensional extension of the manifestly gauge covariant method
Alessandro D’Adda +3 more
doaj +1 more source
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan +9 more
wiley +1 more source
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source

